2. Vitamin D Related/Nuclear Receptor Immunology/Inflammation
  3. VD/VDR Interleukin Related
  4. Tacalcitol

Tacalcitol  (Synonyms: 1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3)

Cat. No.: HY-32337 Purity: 99.71%
SDS
COA
Handling Instructions Technical Support

Tacalcitol (1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3) can promote normal bone growth by regulating calcium ions. Tacalcitol inhibits cancer cell proliferation and migration. Tacalcitol can be used in the research of inflammation, cancer, and skin diseases.

For research use only. We do not sell to patients.

Tacalcitol Chemical Structure

Tacalcitol Chemical Structure

CAS No. : 57333-96-7

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Tacalcitol:

Tacalcitol Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tacalcitol (1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3) can promote normal bone growth by regulating calcium ions. Tacalcitol inhibits cancer cell proliferation and migration. Tacalcitol can be used in the research of inflammation, cancer, and skin diseases[1][2][3][4][5].

Cellular Effect
Cell Line Type Value Description References
HaCaT IC50
2.07 μM
Compound: Tacalcitol
Cytotoxicity against human HaCaT cells after 48 hrs by MTT assay
Cytotoxicity against human HaCaT cells after 48 hrs by MTT assay
[PMID: 24099996]
HL-60 EC50
7.05 nM
Compound: Tacalcitol
Agonist activity at VDR in human HL60 cells assessed as induction of cell differentiation after 96 hrs by NBT reduction assay
Agonist activity at VDR in human HL60 cells assessed as induction of cell differentiation after 96 hrs by NBT reduction assay
[PMID: 24099996]
MCF7 IC50
0.057 μM
Compound: Tacalcitol
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 24099996]
In Vitro

Tacalcitol (0.1-100 μM, 24 h) inhibits synthesis of both IL-6 and IL-8 in cultures derived from nasal polyps in dose-dependent manner[1].
Tacalcitol (10-4-1 μM, 48 h or one week) induces cell differentiation in normal human keratinocytes. Tacalcitol inhibits the growth of normal and psoriatic human keratinocytes[2][3].
Tacalcitol (0-1 μM, 48 h) inhibits DNA synthesis in normal human keratinocytes[3].
Tacalcitol (0.001-10 μM, 6 days) strongly reduces proliferation of human glioblastoma[4].
Tacalcitol (10 μM, 41 h) inhibits human glioblastoma migration[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tacalcitol Related Antibodies

Cell Proliferation Assay[3]

Cell Line: normal human keratinocytes
Concentration: 10-10, 10-9, 10-8, 10-7, 10-6 M
Incubation Time: one week
Result: Significantly inhibited the growth of human keratinocytes at concentrations higher than 10-8 M.
The growth of keratinocytes was 65% inhibited by 10-8 M and 90% inhibited by 10-7 M

Cell Viability Assay[4]

Cell Line: T98G cells
Concentration: 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time: 6 days
Result: Treatment for 6 days resulted in a significant, dose-dependent inhibitory effect on cell viability/growth.
Treatment of cells for less than 6 days did not influence cell viability/growth.

Cell Migration Assay [4]

Cell Line: T98G cells
Concentration: 10 μM
Incubation Time: 41 h (pre-treated for 24 h, then cells were scraped and monitore for 17 h)
Result: Reduced the migration rate.
After 17 hr, the wound closure of control cells was about 60%, while treated cells had a wound closure of about 35-45%.
In Vivo

Tacalcitol (0.2-20 μg/g; applied to the cutaneous inflammation area) ointment has a marked effect on cutaneous inflammation caused by TPA, and improves effect on epidermal differentiation in hairless mice[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female SKH1 (hr/hr) hairless mice (7-8 weeks old, Phorbol 12-myristate 13-acetate (HY-18739) (12-Otetradecanoylphorbol 13-acetate (TPA)) was topically applied to 6 cm2 area of the dorsal skin to induce cutaneous inflammation)[5]
Dosage: 0.2, 2, 20 μg/g
Administration: Applied to the cutaneous inflammation area
Result: Significantly inhibited TPA-induced cutaneous inflammation, histopathologically.
The effect of 20 μg/g on cutaneous inflammation was much stronger than that of 2 μg/g.
20 μg/g also significantly inhibited TPA-induced myeloperoxidase (MPO) activity.
The effect on epidermal proliferation was significant at the doses of 2 μg/g and 20 μg/g, and that on epidermal differentiation was significant at the doses of 0.2 μg/g or more.
Clinical Trial
Molecular Weight

416.64

Formula

C27H44O3
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](CC[C@H](C(C)C)O)C)CCC/2)[H])O)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light, stored under nitrogen

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (240.02 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.4002 mL 12.0008 mL 24.0015 mL
5 mM 0.4800 mL 2.4002 mL 4.8003 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.75 mg/mL (6.60 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.75 mg/mL (6.60 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.4002 mL 12.0008 mL 24.0015 mL 60.0038 mL
5 mM 0.4800 mL 2.4002 mL 4.8003 mL 12.0008 mL
10 mM 0.2400 mL 1.2001 mL 2.4002 mL 6.0004 mL
15 mM 0.1600 mL 0.8001 mL 1.6001 mL 4.0003 mL
20 mM 0.1200 mL 0.6000 mL 1.2001 mL 3.0002 mL
25 mM 0.0960 mL 0.4800 mL 0.9601 mL 2.4002 mL
30 mM 0.0800 mL 0.4000 mL 0.8001 mL 2.0001 mL
40 mM 0.0600 mL 0.3000 mL 0.6000 mL 1.5001 mL
50 mM 0.0480 mL 0.2400 mL 0.4800 mL 1.2001 mL
60 mM 0.0400 mL 0.2000 mL 0.4000 mL 1.0001 mL
80 mM 0.0300 mL 0.1500 mL 0.3000 mL 0.7500 mL
100 mM 0.0240 mL 0.1200 mL 0.2400 mL 0.6000 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tacalcitol Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tacalcitol57333-96-71,24(R)-Dihydroxyvitamin D3 1.alpha.,24R-Dihydroxyvitamin D3VD/VDRInterleukin RelatedVitamin DVitamin D receptorILpsoriasisVitiligohuman keratinocytesinflammationglioblastomanasal polypsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tacalcitol
Cat. No.:
HY-32337
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (479 KB) Français - FR (479 KB) Deutsch - DE (479 KB) Norwegian - NO (479 KB) Español - ES (479 KB) Swedish - SV (479 KB) Italian - IT (479 KB) Portuguese - PT (479 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.